Navigation Links
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Date:5/7/2008

parallel-group, placebo-controlled phase III study to evaluate the safety and efficacy of Lexapro in the treatment of depressed adolescents, aged 12-17, was conducted in multiple centers across the U.S. A total of 316 patients entered the eight week study, receiving either Lexapro 10-20 mg (n=158) or placebo (n=158). The primary endpoint was change from baseline to Week 8 on the Children's Depression Rating Scale - Revised (CDRS-R) using last observation carried forward (LOCF) approach. The CDRS-R is a commonly used clinician-rated instrument that covers 17 symptom areas of depression relevant to adolescents, including impaired schoolwork, difficulty having fun, social withdrawal, physical complaints, and low self-esteem. The study showed statistically significant improvement in patients treated with Lexapro relative to placebo based on the change from baseline in the CDRS-R score (-22.1 for Lexapro vs. -18.8 for placebo treatment; p=0.022).

The trial also showed that Lexapro was generally well-tolerated. Discontinuation rates due to adverse events were 2.6 percent and 0.6 percent for patients receiving Lexapro and placebo, respectively. Serious adverse events were reported by 2.6 percent of patients receiving Lexapro and 1.3 percent for patients receiving placebo. The most commonly reported adverse events (greater than 10 percent in either group) were headache (25 percent in Lexapro patients vs. 26 percent with placebo), menstrual cramps (11 percent vs. 15 percent placebo), nausea (10 percent vs. 8 percent placebo), insomnia (10 percent vs. 6 percent placebo) and inflicted injury (9 percent vs. 13 percent placebo), the majority of which were accidental in nature. The only adverse event occurring at a frequency of greater than or equal to 5 percent and with an incidence for Lexapro treated patients twice that of placebo treated patients was influenza-like symptoms (7 percent vs. 3 percent placebo).

Depression and Adolescents

Adolescent depressio
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
3. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... CMED ), a leading China-based ... its unaudited financial results for the ... 2011 ("1Q FY2011") today.1 Q ...
... More than a decade of targeted Muscular Dystrophy Association-funded ... support of the MDA Labor Day Telethon and thousands ... providing financial assistance for the start of the first ... pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, ...
Cached Medicine Technology:China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 2MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 3MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 4
(Date:4/23/2014)... Washington State University Spokane have developed a new ... nod off behind the wheel. , Their recently ... are more variable in drowsy driversand offers an ... video-based driver drowsiness detection systems. , Van Dongen"Video-based ... car is drifting out of its lane are ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
(Date:4/23/2014)... computer program could help doctors predict which patients might ... , The program, which assesses brain scans using ... security and passport control, has been developed by researchers ... funded by the Wellcome Trust, which used the software ... , Stroke affects over 15 million people each ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
Breaking Medicine News(10 mins):Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... older adults with one of two classes of available drugs ... yearly flu shots are likely a better bet. // ... caring for older adults with the flu or a flu-like ... for flu before treatment with an anti-flu drug, and treating ...
... new study finds whole grains, fruits and vegetables will decrease ... dying. However, the study also reports these foods do not ... Dietary Guidelines for Americans include choosing a variety of fruits ... especially whole grains. While at least five fruits and vegetables ...
... lung cancer before it's in a more advanced stage is ... //can detect early lung cancer, researchers wanted to determine if ... researchers who wanted to look at the cost-effectiveness of a ... part of the Early Lung Cancer Action Project (ELCAP) that ...
... the drug dalteparin is beneficial for diabetic patients with severe ... for diabetic patients and are one of the most expensive ... limb of the diabetic patient. A new study led by ... of the drug dalteparin on foot ulcers in diabetic patients. ...
... they've developed a new way to treat certain kinds ... that emits far more high-energy radioactivity than current radio-isotopes ... tumor cells invade bone marrow. For many years, doctors ... with bone metastases. ,The radio-isotopes ease pain by ...
... vascular dementia find it can help treat the cognitive ... or VaD -- is usually associated with cardiovascular disease. ... of dementia are attributed to VaD. Unlike Alzheimer’s disease, ... time, VaD often strikes quickly, such as after a ...
Cached Medicine News:
... Direct to High Res SSP kits provide high resolution ... Locus specific typing on a single tray reduces QC ... from genomic DNA to high resolution results, no need ... with a single tray , Unique reaction pattern for ...
... the storage of blood plasma in full ... attention to operating temperatures and performance means ... Standard freezer you will minimise bag cracking ... temperature an additional benefit is reduced thawing ...
Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: